A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer

This study explored the safety and preliminary efficacy of the anti-PD-L1 antibody TQB2450 combined with the multi-kinase inhibitor anlotinib in advanced triple-negative breast cancer (TNBC). Patients with advanced TNBC who received at least one line of systemic therapy with anthracyclines and/or ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiayu, Sun, Tao, Ouyang, Quchang, Han, Yiqun, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238930/
https://www.ncbi.nlm.nih.gov/pubmed/37275528
http://dx.doi.org/10.1016/j.isci.2023.106876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238930/
https://www.ncbi.nlm.nih.gov/pubmed/37275528
http://dx.doi.org/10.1016/j.isci.2023.106876

Ejemplares similares